Evidence map›Paper›PMID 25701994›Full record

ArticleThe Lancet. Global health2015

Effectiveness of reactive oral cholera vaccination in rural Haiti: a case-control study and bias-indicator analysis.

Louise C Ivers, Isabelle J Hilaire, Jessica E Teng, Charles P Almazor, J Gregory Jerome, Ralph Ternier, Jacques Boncy, Josiane Buteau, Megan B Murray, Jason B Harris and 1 more

Open access · goldAbstract read
In one paragraph

Article in The Lancet. Global health, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 4 pooled it
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 4 syntheses or guidelines pooled it, 99 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Effectiveness of Oral Cholera Vaccine in Haiti: 37-Month Follow-Up.The American journal of tropical medicine and hygiene · 2016
    Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Effectiveness of the Euvichol® oral cholera vaccine at 2 years: A case-control and bias-indicator study in Haiti.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Diagnosis, Management, and Future Control of Cholera.Clinical microbiology reviews · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Louise C IversDepartment of Medicine, Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA, USA; Department of Global Health and Social Medicine, Boston, MA, USA; Partners In Health, Boston, MA, USA. Electronic address: louise_ivers@hms.harvard.edu.
Isabelle J HilaireZanmi Lasante, St Marc, Haiti.
Jessica E TengDepartment of Medicine, Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA, USA; Partners In Health, Boston, MA, USA.
Charles P AlmazorZanmi Lasante, St Marc, Haiti.
J Gregory JeromeZanmi Lasante, St Marc, Haiti.
Ralph TernierZanmi Lasante, St Marc, Haiti.
Jacques BoncyMinistry of Health and Population, National Laboratory, Port-au-Prince, Haiti.
Josiane ButeauMinistry of Health and Population, National Laboratory, Port-au-Prince, Haiti.
Megan B MurrayDepartment of Medicine, Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA, USA; Department of Global Health and Social Medicine, Boston, MA, USA; Partners In Health, Boston, MA, USA.
Jason B HarrisDepartment of Pediatrics, Harvard Medical School, Boston, MA, USA; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.
Molly F FrankeDepartment of Global Health and Social Medicine, Boston, MA, USA; Partners In Health, Boston, MA, USA.
Brigham and Women's Hospital · USPartners In Health · USHarvard University · US

Funding

Immune Responses to Vibrio cholerae infection and vaccination in HaitiR01AI099243 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HARRIS, JASON B, IVERS, LOUISE C. · 2012 to 2022
$7.9M
Innate and early B cell responses to V. choleraeR01AI103055 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HARRIS, JASON B · 2014 to 2018
$3.9M
NIAID NIH HHS R01 AI099243NIAID NIH HHS R01 AI103055
6 · The paper itself

Abstract

backgroundBetween April and June, 2012, a reactive cholera vaccination campaign was done in Haiti with an oral inactivated bivalent whole-cell vaccine. We aimed to assess the effectiveness of the vaccine in a case-control study and to assess the likelihood of bias in that study in a bias-indicator study.

methodsResidents of Bocozel or Grand Saline who were eligible for the vaccination campaign (ie, age ≥12 months, not pregnant, and living in the region at the time of the vaccine campaign) were included. In the primary case-control study, cases had acute watery diarrhoea, sought treatment at one of three participating cholera treatment units, and had a stool sample positive for cholera by culture. For each case, four control individuals who did not seek treatment for acute watery diarrhoea were matched by location of residence, enrolment time (within 2 weeks of the case), and age (1-4 years, 5-15 years, and >15 years). Cases in the bias-indicator study were individuals with acute watery diarrhoea with a negative stool sample for cholera. Controls were selected in the same manner as in the primary case-control study. Trained staff used standard laboratory procedures to do rapid tests and stool cultures from study cases. Participants were interviewed to collect data on sociodemographic characteristics, risk factors for cholera, and self-reported vaccination. Data were analysed by conditional logistic regression, adjusting for matching factors.

findingsFrom Oct 24, 2012, to March 9, 2014, 114 eligible individuals presented with acute watery diarrhoea and were enrolled, 25 of whom were subsequently excluded. 47 participants were analysed as cases in the vaccine effectiveness case-control study and 42 as cases in the bias-indicator study. 33 (70%) of 47 cholera cases self-reported vaccination versus 167 (89%) of 188 controls (vaccine effectiveness 63%, 95% CI 8-85). 27 (57%) of 47 cases had certified vaccination versus 147 (78%) of 188 controls (vaccine effectiveness 58%, 13-80). Neither self-reported nor verified vaccination was significantly associated with non-cholera diarrhoea (vaccine effectiveness 18%, 95% CI -208 to 78 by self-report and -21%, -238 to 57 by verified vaccination).

interpretationBivalent whole-cell oral cholera vaccine effectively protected against cholera in Haiti from 4 months to 24 months after vaccination. Vaccination is an important component of efforts to control cholera epidemics.

fundingNational Institutes of Health, Delivering Oral Vaccines Effectively project, and Department of Global Health and Social Medicine at Harvard Medical School.

Indexed as

Cholera VaccinesOutcome Assessment, Health CareVaccinationAdministration, OralAdolescentAdultBiasCase-Control StudiesCholeraDiarrheaFecesFemaleHaitiHumansLogistic ModelsMaleCholera VaccinesVaccines, Inactivated

Identifiers

PMID25701994
PMCPMC4384694
OpenAlexW2102172526

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.